BioSpace News Archive

SINOMED, a developer of innovative neuro- and cardiovascular technologies, announced the completion of the 1-year follow-up in the PIONEER-III, randomized global trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent.

Vetter and Rentschler Biopharma, two globally operating Contract Development and Manufacturing Organizations, announced their strategic collaboration, to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain.

Vizient, Inc. has teamed up with medical suppliers to provide relief for hospitals from the strains of delivering patient care, monitoring and rehabilitation services brought on by COVID-19. The new resources and technology offerings address hospitals’ immediate and unique needs but are also designed as sustainable approaches to care delivery and improving patient satisfaction. Medtronic Care Management Services and Zimme

MiMedx Group, Inc., an industry leader in advanced wound care and an emerging therapeutic biologics company, announced the filing of its 2019 Annual Report.

General Biologicals Corporation, a Taiwanese medical device company has developed the GB SARS-CoV-2 Real-Time RT-PCR : a reliable molecular testing kit for the detection of the novel coronavirus in humans.

Centogene N.V., a commercial-stage diagnostics and genetic research company, and the OESIS Network Inc, an innovation network of more than 600 schools across the U.S., announced a partnership for COVID-19 screening of schools.

Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), an online provider of healthcare information, professional training and educational services to healthcare professionals and the public in China , today announced the official launch of patient management services (the “New Services”) as its third major line of business,

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commencement of operations and initiation of collections at its newest ADMA BioCenters plasma collection facility located in Knoxville, TN.

Vir Biotechnology, Inc., a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed underwritten public offering of 6,200,000 shares of its common stock.

Anti-viral antibody cocktail REGN-COV2 is also in Phase 2/3 treatment trials following positive Phase 1 safety review